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ABSTRACT
An acquisition of increased sensitivity of cancer cells to viruses is a common 
outcome of malignant progression that justifies the development of oncolytic viruses 
as anticancer therapeutics. Studying molecular changes that underlie the sensitivity 
to viruses would help to identify cases where oncolytic virus therapy would be 
most effective. We quantified changes in protein abundances in two glioblastoma 
multiforme (GBM) cell lines that differ in the ability to induce resistance to vesicular 
stomatitis virus (VSV) infection in response to type I interferon (IFN) treatment. In 
IFN-treated samples we observed an up-regulation of protein products of some IFN-
regulated genes (IRGs). In total, the proteome analysis revealed up to 20% more 
proteins encoded by IRGs in the glioblastoma cell line, which develops resistance 
to VSV infection after pre-treatment with IFN. In both cell lines protein-protein 
interaction and signaling pathway analyses have revealed a significant stimulation 
of processes related to type I IFN signaling and defense responses to viruses. 
However, we observed a deficiency in STAT2 protein in the VSV-sensitive cell line 
that suggests a de-regulation of the JAK/STAT/IRF9 signaling. The study has shown 
that the up-regulation of IRG proteins induced by the IFNα treatment of GBM cells 
can be detected at the proteome level. Similar analyses could be applied for revealing 
functional alterations within the antiviral mechanisms in glioblastoma samples, 
accompanying by acquisition of sensitivity to oncolytic viruses. The approach can be 
useful for discovering the biomarkers that predict a potential sensitivity of individual 
glioblastoma tumors to oncolytic virus therapy.
                   Research Paper
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INTRODUCTION
Glioblastoma multiforme (GBM) is highly 
aggressive still incurable malignant brain tumor 
[1, 2]. Challenges in glioblastoma treatment include a 
problematic complete surgical removal of the tumor, a 
deep penetration of GBM stem cells into normal brain 
tissue [3, 4], a fast proliferation of malignant cells, and a 
high resistance of glioblastoma stem cells to radiation [5] 
or chemotherapy [6] that drive tumor recurrence [7]. The 
notorious inter- and intra-tumoral heterogeneity of GBM 
cells [8] explains eventual failures of existing targeted and 
immune therapy approaches [9, 10].
Currently, replication competent oncolytic viruses 
are being developed and tested as promising approach 
to therapy of GBMs [11–16]. Cancer cells commonly 
acquire increased sensitivity to replication and killing 
by viruses of many families. Oncolytic viruses are non-
pathogenic naturally occurring or engineered strains of 
viruses that can selectively infect and kill cancer cells 
while sparing cells of normal tissues [17–20]. Besides the 
direct virus replication-dependent cell lysis, the infection 
initiates complex changes in tumor microenvironment 
and activation of both innate and adaptive branches 
of anticancer immunity that contribute to a long-term 
therapeutic effect even after the virus is cleared from 
tumor sites [21–25]. Another important advantage of 
oncolytic viruses is their ability to kill the cancer-initiating 
stem cells, thus, limiting the probability of relapses 
[26–29]. The activity against GBM stem cells has been 
demonstrated for many oncolytic viruses [30–35], and 
some long-term remissions following GBM virotherapy 
in limited clinical trials [36–39] suggest that viruses could 
provide a long lasting cure for the patients. 
During malignant progression, the cancer cells 
accumulate multiple molecular alterations enabling the 
accelerated growth and invasion. However, the loss of 
important control mechanisms comes at the expense of 
the increased sensitivity to viruses [40]. Cancer cells are 
more accessible to viruses because of the disorganized 
architecture of tumors, overexpression or overexposure 
of the surface virus entry receptors and leaky neovascular 
network [41]. Besides, cancer cells generally have 
relaxed metabolic regulation, disrupted cell-cycle 
control, and lost suicidal reaction in response to stresses 
and pathogens [42, 43] that provide additional benefits 
for a robust replication of viruses. Among the main 
targets for inactivation of antiviral mechanisms during 
cancer progression are multiple components of antiviral 
innate immunity, including the IFN induction and IFN 
response mechanisms [40, 44–49]. Inactivation of these 
mechanisms by mutations or epigenetic silencing renders 
cancer cells sensitive to selective killing by oncolytic 
viruses. In previous studies, a number of important 
examples demonstrating a variety of responses of cancer 
cells or patients treated with a particular oncolytic virus 
strain have been reported. The differences in responses 
may be explained by the tremendous variability of specific 
molecular defects in cancer cells. Apparently, an analysis 
of specific defects in antiviral defense mechanisms in 
individual cancer cases may facilitate a personalized 
prediction of clinical responses to oncolytic viruses and 
promote the introduction of this type of therapy to clinical 
practice.
Because of the still lethal prognosis, GBM is one 
of the forefront candidates for oncolytic virus therapy. 
To reveal specific defects affecting the sensitivity of 
GBM cells to viruses, we performed a comparative 
proteomics analysis of two GBM cell lines that differ in 
their responses to treatment with Type I IFN. The core 
of the signaling mechanism behind the IFN response is 
the JAK/STAT pathway [50, 51]. The JAK/STAT cascade 
(Figure 1) is initiated by an interaction of type I IFNs 
(IFNα or IFNβ) to cell-surface receptor molecules leading 
to their dimerization and formation of IFNAR1/2 complex 
that recruits Janus kinases JAK1 and TYK2. The activated 
JAK kinases promote the formation of complex between 
signal transducer and activator of transcription proteins 
STAT1 and STAT2 and its release from the intracellular 
portion of the IFN α/β receptor. The STAT heterodimers 
associate with the IFN regulatory factor ISGF3G/IRF-9 
to form the ISGF3 transcription factor that in the nucleus 
activates IFN-stimulated genes (ISGs) by binding to 
specific IFN-stimulated response elements (ISREs) within 
the genes. The transcription of ISGs can be also affected 
by alternative branches of IFN induced pathways. For 
example, phosphorylated STAT1 can form homodimers 
acting as GAF transcription factor that activates ISGs 
transcription by binding to GAS elements. The JAK/STAT 
cascade can be negatively regulated by suppressors of 
cytokine signaling (SOCS), protein inhibitors of activated 
STATs (PIAS) and protein tyrosine phosphatases (PTPs), 
thus, mediating a downregulation of IFN signaling. 
Alteration of the pathways at different levels may result 
in deregulated responses to IFNs in malignant cells. 
However, there are branches of other signaling pathways 
that affect IFN response mechanisms and may be altered 
in cancer cells [45]. A treatment with Type I IFNs can 
induce apoptosis of some malignant cells in tumors by 
stimulating antitumor innate immune responses [52, 
53]. However, IFNs can also mediate opposite effects, 
such as an increased survival of malignant cells [52, 54]. 
The ambiguities can be explained by different functional 
conditions of IFN signaling in malignant cells. 
In the present study, we explored specific defects 
in antiviral mechanisms of two cell lines derived from 
GBM patients. One of the cell lines, DBTRG-05MG, 
was found to demonstrate a strong response to IFN-a 
treatment, which completely protected the cells from 
infection with vesicular stomatitis Indiana virus (VSV), 
while the A-172 GBM cell line retained high sensitivity 
to the virus regardless of the IFN treatment. By applying 
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a shotgun LC-MS/MS-based proteomics and label-free 
quantitation of identified proteins, we mapped proteomes 
of both cell lines and analyzed the changes in protein 
expressions after IFN-a treatment. The revealed changes 
in protein components of IFN signaling reflect the 
molecular alterations that suggest being responsible for 
the individual sensitivity/resistance of GBM patients to 
oncolytic viruses.
RESULTS AND DISCUSSION
Analysis of changes in protein abundances 
induced by the IFN treatment
Statistical analysis using paired t-test for dependent 
samples (workflow A, see M&M) revealed 109 and 199 
proteins with Benjamini-Hochberg false discovery rate 
fdrBH < 0.05 for A-172 and DBTRG-05MG, respectively. 
To understand how the calculated p-values are correlated 
with abundance fold changes (FC) for all proteins 
examined in t-test, the uncorrected protein p-values were 
plotted against the FC in logarithmic scale, −log2 (pvalue) 
vs. log10 (FC IFN/K) (Figure 2).
As shown in Figure 2A and 2B, there is a group 
of proteins above the threshold fdrBH = 0.05, but the 
abundance fold changes for many of these proteins do not 
diverge significantly, and it ranges from 0.4 to 2.5. Based 
on this observation, we considered only proteins with 
abundance fold changes FC ≤ 0.4 and FC ≥ 2.5 for down- 
and up-regulation, respectively, for the further analysis 
(Figure 2, Green Areas).
Comparison of statistical workflows
Since an application of the paired t-test to both 
normally distributed (ND) and not normally distributed 
(NND) data (workflow A) can generate inaccurate 
p-values for the NND data, and, thus, bias results, we 
Figure 1: Scheme of canonical JAK/STAT cascade initiated by type I IFN binding to cytokine receptor as described 
elsewhere [50–51]. Labels: pY – phosphorylated tyrosines.
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split the data into two groups, ND and NND, based on 
the results of the Shapiro-Wilk test. At the next step, the 
paired t-test and the Kruskal-Wallis test were respectively 
applied to the ND and NND data and the results for 
each group were corrected for multiple comparisons 
before being combined (workflows B and C). Workflow 
C also reflects the effect from the imputation of missing 
protein identifications. Comparison of the workflows is 
shown in Venn diagrams in SI Supplementary Figure 1. 
Notably, results of the paired t-test applied to both ND 
and NND data were supported at least by either workflow 
B or C; workflow B actually contains only the results of 
paired t-test applied to ND data, because the correction of 
results of the Kruskal-Wallis test for multiple comparisons 
did not pass any proteins. The proteins identified as 
differentially expressed according to workflow A and B 
are provided in Supplementary Table 1. Relative protein 
quantities measured in the control and treated samples and 
processed using workflow A visibly differ (Supplementary 
Table 1). Note, that results obtained using the paired t-test 
(ND+NND, fdrBH < 0.05) (workflow A) contain 15% 
and 9% of proteins with NND abundances for A-172 
and DBTRG-05MG lines, respectively. Most of these 
proteins (exceptions: O75534-2 in A-172 and P07602-3 in 
DBTRG-05MG) were supported by running the Kruskal-
Wallis test applied to NND data after the missing value 
imputation (fdrBH < 0.05) (workflow C); Kruskal-Wallis 
p-values are also provided (Supplementary Table 1). Since 
the Kruskal-Wallis test is a non-parametric test, zeroing 
the missing protein identifications does not bias the results. 
Therefore, we are confident with the proteins identified 
using workflow A. Further analysis in the study is basically 
grounded on the results obtained using workflow A, if not 
stated otherwise.
Studying the proteins with statistically 
significant changes in expression
When analyzing the proteins with statistically 
significant changes in expression, we divided proteins 
into two groups: (1) differentially expressed proteins 
identified both in IFN treated and in control samples; 
and (2) proteins identified either in IFN treated, or in 
control samples, only. Note that the first group includes 
all proteins inside the Green Areas in the Volcano plots 
(Figure 2), while the second group includes proteins with 
null abundance in either treated, or control samples, i.e. 
log10 FC IFN/K cannot be determined for them. 
The differentially expressed proteins from the first 
group and their encoding gene names are shown in Figure 
3. As it can be seen for the A-172 cell line, 24 up-regulated 
and 9 down-regulated proteins with more than 2.5-fold 
differences in abundance have passed through the chosen 
filtration criteria (Figure 3A). Among the up-regulated 
proteins, 14 proteins were encoded by IFN-regulated genes. 
For the DBTRG-05MG cell line, 55 up-regulated and 15 
down-regulated proteins were identified as responsive 
to IFN treatment (Figure 3B). Among the up-regulated 
proteins, 15 proteins are encoded by the IFN-regulated 
genes, according to the INTERFEROME db search.
All proteins that changed their detection status (i.e. 
detected to non-detected and vice versa) in response to 
Figure 2: Analysis of protein fold changes in Volcano plots. (A) A-172 cell line sensitive to VSV after IFN treatment; (B) 
DBTRG-05MG cell line resistant to VSV after IFN treatment. Legends: FCIFN/K, FC – fold change expressed as a ratio of the average protein 
normalized spectral index in IFN treated samples to the average spectral index of the same protein in control samples; p-value – t-test 
uncorrected p-value; fdrBH – Benjamini-Hochberg FDR. Green areas denote differentially expressed proteins with Benjamini-Hochberg 
FDR < 0.05 and abundance fold changes ≥ 2.5 and ≤ 0.4 for up-regulated and down-regulated proteins, respectively.
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IFN treatment are listed in Figure 4. As noted above, for 
both cell lines this group contains up-regulated proteins, 
most of which are IRGs encoded. Thus, all 14 proteins 
identified only in the IFN-treated samples of the A-172 
cell line were referenced as the IFN-regulated genes 
(Figure 4A). For the DBTRG-05MG cell line, 19 of 31 
up-regulated proteins are the products of IRGs.
In summary, the following results for differentially 
expressed proteins satisfying Benjamini-Hochberg’s 
criteria of FDR < 0.05; FC ≥ 2.5; FC ≤ 0.4 were obtained: 
34 and 28 IRGs proteins were up-regulated after IFN 
treatment for DBTRG-05MG and A-172 cell lines, 
respectively. Thus, the number of IRGs proteins identified 
for the IFN-responsive DBTRG-05MG cells was higher 
by ~20% compared with the IFN-unresponsive A-172 
cells. Note that the two glioblastoma cell lines have shared 
only ~40% of the identified IRGs proteins (Supplementary 
Figure 2).
The experimental evidences reported earlier have 
shown that the strength of antiviral defense correlates 
with the number of detected products of IFN-stimulated 
genes. It has been suggested that a larger number of IFN-
stimulated genes is detected for the cells that exhibit 
stronger antiviral defenses [55]. Our results further support 
this hypothesis. 
Gene ontology (GO) analysis
To find the biological processes that were enhanced 
after the IFN treatment, gene ontology analysis of 
Figure 3: Proteins identified in both IFN-treated and control samples, change their abundance after IFN treatment. 
(A) A-172 cell line sensitive to VSV after IFN treatment; (B) DBTRG-05MG cell line resistant to VSV after IFN treatment. Proteins satisfy 
criteria fdrBH < 0.05, FC ≤ 0.4 and ≥ 2.5. The p-values and FC values characterize proteins encoded by the respective genes which are 
denoted at the Y axis.
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differentially expressed proteins satisfying criteria fdrBH 
< 0.05, FC ≤ 0.4 and ≥ 2.5 was performed. The proteins 
derived using statistical workflows A and C were analyzed 
using INTERFEROME, STRING and GOrilla databases 
[56–58]. The results are shown in Supplementary Table 2 
and Supplementary Table 3 for workflows A and C, 
respectively. 
As shown in Supplementary Table 2, all the applied 
tools for both A-172 and DBTRG-05MG cell lines reveal 
that the prevailing changes belong to processes related 
to immune responses and IFN-mediated signaling. In 
addition, results for the A-172 cell line reveal antigen 
processing and presentation of peptide antigens by MHC 
class I processes. In case of the STRING database analysis, 
the antigen processing and presentation of peptide antigens 
by MHC class I processes were observed at higher false 
discovery rate of 0.02 and did not fall into top-20 biological 
processes. Protein-protein interaction networks for proteins 
expressed differentially in the treated samples were also 
generated (Figure 5A, 5B). The interaction networks for 
both cell lines cover most of the statistically relevant 
differentially expressed proteins. It can be noticed that 
most of the identified IRGs-encoded proteins are present 
in the interactome patterns: ~90% and ~80% for A-172 
and DBTRG-05MG cell lines, respectively. In Figure 5, 
the networks cover ~70% and ~60% of all differentially 
expressed proteins identified for A-172 and DBTRG-
05MG, respectively. Both networks can be considered 
as biologically related groups; however a functionally 
related protein group in the DBTRG-05MG cell line with 
preserved ability to develop antiviral resistance in response 
to IFN counts noticeably more proteins.
A GO analysis was also performed with the 
differentially expressed proteins identified in workflow 
C. As this workflow revealed significantly more proteins, 
we expected to get better insight into the pathways and 
clarify whether the enrichments within the MHC class I 
processes are specific to A-172 line. Results of the GO 
analysis (workflow C) are presented in Supplementary 
Table 3 (Supplementary Information). INTERFEROME 
and GOrilla provided very similar results revealing the 
top enriched processes for the A-172 cells line, that are 
cytokine signaling, defense / immune response and antigen 
processing and presentation of peptide antigens by MHC 
class I. The results agree well with the GO enrichments 
obtained from workflow A protein lists (Supplementary 
Table 2). However the results of STRING show noticeable 
differences, as the tool identifies first cellular component 
/ organelle organization processes, instead of the IFN 
signaling and defense response (Supplementary Table 3). 
We assume that STRING could generate inaccurate p-values 
for the biological processes involving hundreds of proteins 
when the large target list (here from 500 to 600 proteins) is 
searched against the whole genome statistical background.
In summary, gene ontology analysis performed 
with three different tools identifies type I IFN signaling 
and defense response pathways as those showing major 
changes after IFN treatment. These pathways are the 
expected responders to the treatment. Besides, we 
suggest that the enrichment of the MHC class I antigen 
presentation process relates to the response to IFN 
treatment in A-172 cells that are not protected against 
VSV infection. These processes are considerably less 
stimulated by IFN in the IFN-responsive DBTRG-05MG 
Figure 4: Proteins identified in either IFN treated samples or control samples. (A) A-172 cell line sensitive to VSV after IFN 
treatment; (B) DBTRG-05MG cell line resistant to VSV after IFN treatment.
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cells. Reportedly, downregulation of MHC class I genes 
is responsible for the increased survival of cancer cells 
due to immune escape mechanisms [59]. The activation 
of STAT1 by IFNs may promote antitumor activity on 
oncolytic viruses in vivo, partly by upregulating MHC 
class I-mediated antigen presentation by tumor cells [60].
Analysis of the type I IFN signaling in A-172 and 
DBTRG-05MG cell lines
We performed a comparative analysis of major 
components of the IFN response pathway to find 
functional differences between type I IFN signaling 
in A-172 and DBTRG-05MG cell lines. JAK/STAT 
(Figure 1) is the principal cascade behind the type I 
IFN signaling. The canonical scheme for this pathway 
includes several major components: IFNAR1/2 receptors, 
JAK1/TYK2 kinases, signal transducers and activators 
of transcription STAT1/2, as well as the IFN regulatory 
factor IRF9. A functional JAK/STAT cascade induces 
a transcription of multiple IFN-stimulated genes that 
drives the cell into the antiviral state in response to IFN 
treatment. Supplementary Table 4 shows matching major 
protein components of the JAK/STAT cascade within 
the proteomes of GBM lines under study. Specifically, 
interferons (IFNs), IFN receptors (INAR, INGR), Janus 
kinases (JAK, TYK), signal transducers and activators of 
transc ription (STAT), and interferon regulatory factors 
(IRF) were searched against the proteome of each cell 
line. Then, the protein’s q-values and t-test’s p-values for 
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matched proteins were extracted from the search and t-test 
results as measures of protein false discovery rate and 
statistical significance of the abundance change. As the 
result, the STAT protein family can be highlighted due to 
its elevated presence in the treated samples and a regular 
identification in most runs of samples. Noteworthy, STAT1 
and STAT2 from the STAT protein family were identified 
in all data sets obtained for the IFN-treated DBTRG-
05MG line, while being absent in the control samples. 
That resulted in an extremely low t-test’s p-values and 
statistically significant increase in the corresponding 
protein expression. The A-172 cell line exhibited different 
results for identification of proteins of the STAT family. 
Specifically, STAT1 was first identified in the untreated 
control samples. Then, it was found in the treated samples 
at significantly higher concentrations. STAT2 was not 
observed in untreated samples and was identified at < 0.01 
protein FDR in half of all runs performed for the treated 
samples. Thus, in workflow A, STAT2 protein has not 
passed statistical threshold; therefore, its regulation was 
initially treated as unchanged.
Deficiency in the product of signal transducer 
and activator of transcription STAT2 for the VSV-
sensitive (not protected by IFN) cell line could suggest a 
downregulation of the canonical JAK/STAT cascade that 
involves the formation of the ISGF3 complex required for 
Figure 5: Protein-protein interaction networks for proteins differentially expressed in: (A) A-172 cell line, which is 
sensitive to VSV after type I IFN α-2b treatment; (B) DBTRG-05MG cell line, which develops resistance to VSV after 
type I IFN α-2b treatment. Pink ovals denote the IRG-encoded proteins not involved in the interactome network. The networks were 
generated using STRING v.10.0. Proteins obtained using statistical workflow A were used in evaluation. * Note: Since nardilysin isoform 2 
(NRD2) was not found in the STRING db, nardilysin NRD1 was submitted instead.
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the induction of antiviral state. To reveal the expression 
status of STAT1 and STAT2 genes, levels of corresponding 
transcripts were quantified by real-time qPCR. Relative 
levels of STAT2 protein were also measured by Western 
blot analysis. Results of real-time qPCR, LC-MS/MS-
based label-free quantitation and Western blot analysis 
are compared in Figure 6. The results demonstrate that 
patterns of expression of the genes measured at the 
level of transcripts and proteins are consistent. Higher 
normalized expression levels of STAT1 can be noticed 
for both IFN-treated cell lines, compared with the lower 
expression levels of STAT2. By PCR measurement the 
STAT1 to STAT2 ratios were 4 and 13, for DBTRG-
05MG and A-172 cells, respectively. In the IFN-treated 
cells STAT1 expression increased 2.0 and 2.8-fold, while 
expression levels of STAT2 increased 6.8 and 18.5-fold for 
DBTRG05MG and A-172 cells, respectively. Meantime, 
a normalized expression of STAT2 in the IFN-treated 
DBTRG-05MG cells was 1.6-fold higher, as compared 
to the IFN-treated A-172 cells, while the expression of 
STAT1 was 2-fold lower. Probably, a higher response of 
STAT1 in A-172 cells represents a compensatory effect 
due to the deficiency of STAT2. Results of western blot 
analysis clearly show a significantly higher level of total 
STAT2 protein in the IFN-treated DBTRG-05MG cells. 
Note that protein quantities in this study were measured for 
the whole cell extracts without specific analysis of protein 
modifications. Meantime, the quantities of phosphorylated 
STAT1 and STAT2 proteins correlate strictly with a 
regulation status of the JAK/STAT cascade. Thus, in 
A-172 cells, a downregulation of the direct signaling 
via ISGF3 complex formation and/or an upregulation 
of the minor pathway involving GAF element could be 
suggested. However, more studies are required to verify 
this hypothesis. 
Analysis of the defense responses in A-172 and 
DBTRG-05MG cells
Next, in the GBM cells we compared expression 
profiles of proteins that belong to the defense response 
pathway (GO: 0006952). The use of STRING db has 
identified 23 and 25 protein-encoding genes that belong 
to this pathway and are increased in A-172 and DBTRG-
05MG cells, respectively. The intersection between 
the observed genes is not high and comprises ~40% of 
all genes of the pathway (Venn diagram, Figure 7). The 
comparison for the two GBM cell lines has revealed a 
number of similarities and differences. For example, the 
MX, OAS, and EIF2AK2/PKR proteins comprise core 
proteins that reportedly protect against many different 
viruses [61]. The expression of MX and EIF2AK2 proteins 
were identified at similar levels for both cell lines, while 
the OAS proteins demonstrate a higher expression in 
the IFN-responsive DBTRG-05MG cells. Note that an 
up-regulation of OAS1 was found in the IFN-treated 
DBTRG-05MG cells at a level not reaching the statistical 
threshold, and the OAS1 protein was not detected in the 
A-172 samples (not shown in Figure 7). A product of the 
NMI (NMYC interactor) gene is capable of stimulating 
transcription of many STATs, except STAT2 [http://www.
genecards.org/cgi-bin/carddisp.pl?gene=NMI]. We found 
that the NMI protein has similar expression levels in both 
cell lines.
Proteins of the TRIM family are also expressed 
at higher level in the VSV-resistant (IFN-responsive) 
DBTRG-05MG cells. The upregulated proteins include 
TRIM25, a positive regulator of RIG-I/DDX58 helicase 
[62] that plays a key role in sensing viral components and 
initiating secretion of IFNs by infected cells. Meantime, 
ISG15 that can interact with IFIT1, MX1/MX2, EIF2AK2/
PKR, and DDX58/RIG-I proteins is up-regulated at 
similar levels in both cell lines.
An isoform protein of PML gene (PML-2) was 
found increased in the IFN-treated A-172 cells, while 
this protein was not identified in the DBTRG-05MG 
cells. Reportedly, serine phosphorylation induces PML 
accumulation and sumoylation that is required for the pro-
apoptotic activity of PML in response to a DNA damage 
(source: http://www.uniprot.org/uniprot/P29590). Nuclear 
autoantigen SP-100 was upregulated 2-fold in the VSV-
sensitive A-172 cells. SP-100 and PML proteins are the 
main components of the PML bodies that are involved 
in a range of processes including tumor suppression, 
transcriptional regulation, apoptosis, DNA damage 
response, and antiviral defense [source: http://www.
uniprot.org/uniprot/P23497].
Galectin-3 protein stimulating immune/defense 
response was found up-regulated in the DBTRG-05MG 
cells, while an up-regulation of galectin-3-binding protein 
LGALS3BP was observed in the A-172 cells. In the IFN-
treated DBTRG-05MG cells the expression of LGALS3BP 
gene was detected at increased level, however it did 
not pass a statistical threshold (Workflow A). While all 
components of the IFN-dependent multiprotein complex 
comprising antiviral IFIT1, IFIT2, and IFIT3 proteins 
were found in the DBTRG-05MG cells, there were no 
statistically significant changes in the abundance of IFIT2 
in the A-172 cells. However, IFIT5 protein was found at 
higher abundance in these cells.
In general, the comparative analysis has revealed 
higher expressions of proteins belonging to OAS, IFIT, and 
TRIM families in the DBTRG-05MG cells, as the main 
difference between the cells lines that can account for the 
differential sensitivity of GBM cells to viral infection after 
IFN treatment. Core components of JAK/STAT cascade, 
STAT1 and STAT2 proteins, were differentially expressed 
in the cell lines under study. STAT1 was observed at 
higher level in the IFN-treated A-172 cells compared to 
the DBTRG-05MG, while the expression level of STAT2 
was higher in the IFN-treated DBTRG-05MG cells. The 
IFN-induced expression of PML-2 isoform implicated as 
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Figure 6: Relative quantities of STAT1 and STAT2 in IFN-resistant A-172 and IFN-sensitive DBTRG-05MG cell lines: real time qPCR 
(A), LC-MS/MS-based LFQ (B), western blot (C). Whiskers show standard deviations, ±σ. β-Actin equally expressed in the cells under 
study was used as a reference in western blot analysis.
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a potential suppressor in tumors of central nervous system 
[63], is characteristic to A-172 cells. These results suggest 
that although A-172 cells have apparently lost the ability 
to respond to IFN by forming resistance to viral infection 
and have alterations within the JAK/STAT pathway, they 
still retain some IFN-mediated responses that might be 
beneficial for the malignant phenotype.  
In conclusion, by LC-MS/MS analysis we compared 
proteomes of two GBM cell lines that exhibit different 
sensitivity to viral infection after type I IFN treatment. 
Of these, the A-172 cells were highly sensitive to VSV 
infection even after the treatment with IFN, and the 
DBTRG-05MG GBM cells demonstrated a strong 
protection against VSV infection even after treatment 
with low doses of IFN and seemingly retained the 
intact antiviral IFN response mechanisms. Label-free 
quantitation and statistical analysis of protein abundances 
performed for both IFN-treated and control samples have 
revealed the up-regulation of proteins encoded by the 
IFN-regulated genes in the treated cell lines. Specifically, 
the number of proteins encoded by IFN-regulated genes 
and identified for the DBTRG-05MG cell line that can be 
protected by IFN treatment from virus infection was up 
to 20% higher than those in the A-172 cells with a broken 
antiviral IFN response. GO analysis of proteins that are 
differentially expressed in response to IFN treatment has 
revealed the enrichment of biological processes related 
to type I IFN signaling and defense responses to viruses. 
In particular, an enrichment of the MHC class I-mediated 
antigen presentation was observed in IFN treated samples 
of virus-sensitive A-172 cells. Analysis of protein 
expression profiles has also revealed a lower expression 
of STAT2 protein in A-172 cells. Particularly, the change 
in abundance of STAT2 after IFN treatment was found 
statistically insignificant, and, thus, the A-172 cells can 
be considered STAT2-deficient, unlike the DBTRG-05MG 
cells. On the contrary, the relative abundance of STAT1 
product was found at higher level in virus-unprotected 
A-172 cells. Presumably, the observed overexpression of 
STAT1 could be due to a compensatory process.  In A-172 
cells, a downregulation of the direct signaling via ISGF3 
complex formation and an upregulation of the pathway 
Figure 7: Comparison of the proteins related to defense response pathway (GO: 0006952) in the cell lines under study. 
Whiskers show standard deviations: ±σ.
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involving GAF element could explain the compromised 
antiviral response. However, testing this hypothesis 
would require additional experiments to quantify active 
phosphorylated forms of STAT1 and STAT2 proteins, 
reflecting the actual status of IFN-signaling in the lines 
under study. Expression levels of STAT1 and STAT2 were 
also proved by real time qPCR and western blot analysis. 
For both cell lines, normalized gene expression coincided 
well with LC-MS/MS-based label-free quantitation of 
STAT1 and STAT2 proteins. This further suggests that 
the type I IFN signaling, particularly, the JAK/STAT 
cascade leading to the formation of ISGF3 complex, can 
be compromised in the VSV-sensitive A-172 cells. The 
revealed deficiency comes along with a lower number 
of IFN-stimulated genes encoding proteins with antiviral 
activity and, thus, a weaker antiviral defense response. 
Changes in JAK-STAT pathway are common in 
cancer, as alteration in STATs not only modify cytokine-
mediated responses, but also may affect epigenetic 
regulation, promote the self-renewal of niche formation 
for cancer stem cells, and assist in the establishment of 
the immunosuppressive tumor microenvironment.  This is 
why the direct and mediated mechanisms of JAK-STAT 
signaling in tumor cells is becoming a favorite target for 
cancer therapy [64]. Our results indicate that changes in 
JAK-STAT pathway may also correlate with the increased 
sensitivity of cancer cells to oncolytic viruses. Further 
identifying most common changes in the pathway in 
connection with the functional state of IFN-mediated 
antiviral responses may provide useful biomarkers for 
predicting responses to oncolytic viruses in patients. We 
conclude that proteome analysis represents a potentially 
powerful tool for the identification of functional alterations 
within pathways that account for antiviral defenses of 
cancer cells. Certainly, a direct killing of cancer cells that 
can be seen in the in vitro models represents only part of 
the mechanisms underlying activities of oncolytic viruses 
in patients.  Modulation of anticancer immunity, as well 
as virus-induced changes in tumor microenvironment 
may strongly affect the outcome of oncolytic virus 
therapy [18, 65]. However, the selective ability of cancer 
cells to support viral infection is believed to be of prime 
importance, ensuring multiple rounds of viral replication 
in the tumor and the induction of secondary events, 
including the immune-mediated attacks on cancer cells. 
This is why we believe that the analysis tested in this 
study could be extended to more tumor samples from 
GBM patients to find new expression biomarkers useful 
for predicting clinical responses to oncolytic virus therapy.
MATERIALS AND METHODS
Cell lines and virus sensitivity analysis
Two commercially available cell lines of GBM, 
DBTRG-05MG (ATCC® CRL-2020™) and A-172 
[A172] (ATCC® CRL-1620™) have been obtained 
from American Type Culture Collection. The cells were 
grown in DMEM medium (PanEco, Moscow, Russia) 
supplemented with 10% fetal bovine serum (Gibco, 
Thermo Fisher Scientific, Waltham, MA, USA). For IFN 
sensitivity tests, the cells were seeded at the density of 
5000 cells/well to 96-well plates and incubated for 24 hrs 
at 37ºC in 5% CO2 atmosphere. IFN α-2b (Farmaclon, 
Moscow, Russia) was added to samples at concentrations 
of 100, 200, 500, 1000, 2000, 5000 units/ml and incubated 
for the next 24 hours under same conditions. The cells 
were kept sub-confluent by the time of infection with VSV. 
The treated and untreated (control) samples were infected 
with VSV (Indiana strain) at the multiplicity of infection 
(MOI) of 1. Cytopathic effects (CPE) were estimated 
after 24 and 48 hrs of the treatment. IFN-treated DBTRG-
05MG cells were found resistant to VSV (no CPE was 
observed even at minimal (100 units/ml) concentration of 
IFN α-2b). IFN-treated A-172 cells have demonstrated a 
complete degradation after 48 hrs of infection with VSV, 
even if pretreated with maximal dose (5000 units/ml) of 
IFN α-2b (Supplementary Figure 3). The DBTRG-05MG 
cell line was assumed to be an IFN-sensitive, in terms of 
the protection against VSV infection, and the A-172 cell 
line was found to be IFN-insensitive, meaning that it does 
not reach the antiviral state.
Two independently prepared sets of both DBTRG-
05MG and A-172 cells, one treated with IFN α-2b at 
concentration of 100 units/ml for 24 hours, and the untreated 
control (C), were subjected for LC-MS/MS-based proteomic 
analyses. The sub-confluent cell cultures were grown and 
treated in 6 cm culture plates. The cells were scraped from 
the surface, washed 3 times with cold PBS (phosphate 
buffered solution), pelleted by low speed centrifugation and 
stored in liquid nitrogen until further use.
Real time qPCR, relative quantitation
Real-time PCR was performed with SYBR Green 
qPCR master mix (USB) in a CFX96 Touch™ Real-
Time PCR Detection System (Bio-Rad, U.S.A.). The 
PCR protocol was: initial activation at 95°C for 5 min, 40 
cycles at 95°C for 10 s and 60°C for 40s. Ct values were 
converted into relative gene expression levels compared to 
that of internal control gene, GAPDH. Each PCR run was 
performed in quadruplicate. The primer sequences were as 
follows: STAT1-F, ATGGCAGTCTGGCGGCTGAATT; 
STAT1-R, CCAAACCAGGCTGGCACAATTG; STAT2-F, 
CAGGTCACAGAGTTGCTACAGC; STAT2-R, CGGTG 
AACTTGCTGCCAGTCTT.Primers were purchased from 
DNA-Synthesis Ltd. (Moscow, Russia).
Western blot analysis
Cells were lysed with the M-PERTM mammalian 
protein extraction reagent (Thermo Scientific, Germany) 
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with addition of 1% cOmpleteTM EDTA-free protease 
inhibitor cocktail (Roche Diagnostics, Germany). The 
supernatant was separated by centrifugation at 13,000 
rpm for 10 min at 4 °C. Total protein concentration was 
measured using Quick StartTM Bradford protein assay 
kit (Bio-Rad, USA). Protein samples were mixed with 
5×Laemmli loading buffer [66], denatured at 100oC for 
5 min, then cooled and stored at −20°C until further use. 
Protein aliquots from each sample (10μg) along with a 
protein marker (PageRulerTM Plus pre-stained protein 
ladder, Thermo Scientific, Germany) were separated by 
12% SDS-PAGE, and transferred to a membrane (PVDF, 
AmershamTM Hybond® P, GE Healthcare) at 80V for 3 h. 
The electrophoresis and transfer to PVDF membrane were 
performed using Mini-PROTEAN Tetra cell (Bio-Rad, 
USA). Membranes were blocked in a phosphate buffered 
saline - Tween solution (PBST, 137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4, and 
0.1% Tween-20) containing 5.0% of nonfat dry milk for 
1 h at room temperature. Blotted membranes were then 
incubated with primary Rabbit monoclonal antibodies to 
Stat2 (D9J7L, Cell Signaling Technology, USA) at 1:1000 
dilution, overnight at 4 °C, washed 3 times in PBST for 
10 min, and incubated for 1 h at room temperature with 
secondary HRP-labeled mouse anti-Rabbit antibodies 
(Santa Cruz Biotechnology) at 1:5000 dilution. Finally, 
blots were rinsed in PBST 3 times for 10 min and 
visualized using ECLTM Plus Western Blotting Detection 
System (AmershamTM, GE Healthcare) and ChemiDoc™ 
Imaging System (Bio-Rad, USA).
Sample preparation for LC-MS/MS. 
Aliquotes of 106 cells were resuspended in 100 μL of 
lysis buffer containing 0.1 % w/v ProteaseMAX Surfactant 
(Promega, USA) in 50 mM ammonium bicarbonate, and 
10% v/v ACN. The cell lysate was stirred for 60 min at 
1000 rpm at room temperature. Cell lysis was performed 
using ultrasonic homogenizer Bandelin Sonopuls 
HD2070 (Bandelin Electronic, Berlin, Germany). Cells 
were sonicated for 5 minutes at 30% amplitude on ice. 
The supernatant was collected after centrifugation at 
13000 rpm for 10 min at room temperature (Centrifuge 
5415R; Eppendorf, Hamburg, Germany). Total protein 
concentration was measured using Pierce quantitative 
colorimetric peptide assay (Thermo Scientific, Bremen, 
Germany). Protein extracts were reduced in 10 mM 
DTT at 56ºC for 20 min and alkylated in 10 mM IAA 
at room temperature for 30 min in dark. Then, samples 
were overnight digested at 37ºC using trypsin protease 
(Sequencing Grade Modified Trypsin, Promega, Madison, 
WI, USA) added at the ratio of 1:50 w/w. Enzymatic 
digestion was terminated by the addition of acetic acid 
(5% w/v). After the reaction was stopped, the sample 
was stirred (500 rpm) for 30 min at 45ºC followed by 
centrifugation at 15 700× g for 10 min at 20ºC (Centrifuge 
5415R; Eppendorf). The supernatant was then added to the 
filter unit (10 kDa; Millipore, Billerica, MA, USA) and 
centrifuged at 13 400 × g for 20 min at 20ºC. After that, 
100 μL of 50% formic acid was added to the filter unit 
and the sample was centrifuged at 13 400× g for 20min at 
20ºC. Samples were dried using a vacuum concentrator at 
45ºC. Dried peptides were stored at −80ºC until the LC-
MS/MS analysis.
LC-MS/MS analysis
Prior to LC-MS/MS analysis, the samples were 
desalted using Oasis cartridges for solid phase extraction 
(Oasis HLB, 1cc, 10mg, 30µm particle size, Waters). Then, 
the peptide concentration for each sample was measured 
using amino acid analysis. Loaded sample quantity was 
1 μg per injection. LC-MS/MS analysis was performed 
using Orbitrap Fusion Lumos mass spectrometer (Thermo 
Scientific, San Jose, CA, USA) coupled with UltiMate 
3000 nanoflow LC system (Thermo Scientific, Germering, 
Germany). Trap column µ-Precolumn C18 PepMap100 
(5µm, 300µm i.d.x 5 mm, 100Å) (Thermo Scientific) 
and analytical column EASY-Spray PepMap RSLC C18 
(2 µm, 75µm i.d. x 500 mm, 100Å) (Thermo Scientific) 
were employed for separations. Column temperature was 
set to 50ºC. Mobile phases were as follows: (A) 0.1% FA 
in water; (B) 95% ACN, 0.1% FA in water. Samples were 
pre-concentrated for 10 min on a trap column at 5%B. 
Then, peptides were eluted using a linear gradient from 
5%B to 20%B for 105 min followed by a linear gradient 
to 32%B for 15 min at 270 nL/min flow rate. The column 
was washed at 95%B for 10 minutes and equilibrated to 
the start concentration of mobile phase B.
Mass spectrometry measurements were performed 
using data-dependent acquisition (DDA) mode (Top 
Speed, 3s/cycle). Electrospray high voltage was set to 2.0 
kV. Electrospray capillary temperature was 275ºC. MS1 
settings were as follows: mass range m/z from 375 m/z 
to 1,500 m/z, resolving power of 120,000 at m/z 200, 
maximum injection time was set to 50 ms, the automatic 
gain control (AGC) for MS1 was 4.0e5, the dynamic 
exclusion was set to 60 s. Precursor ions were isolated in 
the m/z window of 0.7 Th followed by their fragmentation 
using higher-energy collision dissociation (HCD) at 
normalized collision energy (NCE) of 30%. Fragment 
ions were measured in the Orbitrap mass-analyzer with 
resolving power of 30,000 at m/z 200. Maximum injection 
time during MS/MS was 60 ms with AGC value of 2.0e5.
Protein identification and quantitation. 
Thermo raw files were converted to mgf format using 
a command line tool msсonvert distributed via ProteoWizard 
project (http://proteowizard.sourceforge.net/tools.shtml). 
Database search was performed using X!Tandem (version 
CYCLONE 2012.10.01.1) against the combined target-
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decoy database (db). The target db was SwissProt human 
(access date Dec 2016); the decoy db was compiled by 
reversing the protein sequences from the target db. Search 
parameters were as follows: 10 ppm for precursor mass 
tolerance; 0.01 Da for fragment mass tolerance; maximum 
2 missed cleavage sites; fixed carboxyamidomethylated 
cysteines; potential methionine oxidation, phosphorylation 
on tyrosine, serine and threonine, and acetylation of lysine 
and protein N-terminus. Pepxmltk was used to convert 
tandem t.xml into pep.xml format [67]. Filtration of the 
results to 1.0% protein false discovery rate [68], post-
search validation, as well as label free quantitation were 
performed using MPscore [69]. MPscore reported ~3000 
and ~4000 protein groups for DBTRG-05MG and A-172 
samples, respectively. Calculations of protein abundances 
using three label-free quantitation (LFQ) methods are also 
implemented in MPscore: normalized spectral index (SIN) 
[70], normalized spectral abundance factor (NSAF) [71] and 
exponentially modified protein abundance index (emPAI) 
[72]. To eliminate global technical biases, protein intensities 
were normalized. The results of this normalization 
showing no global shifts for the data are presented in 
Supplementary Figure 4. In this study, we evaluated the 
statistically significant changes in protein expression for 
the results obtained using all three quantitation methods. 
Data analysis using NSAF- and emPAI-calculated protein 
abundances resulted in almost identical patterns for 
differentially expressed proteins, while statistical analysis 
using SIN method provided 20% and 30% larger amount of 
differentially expressed proteins for DBTRG-05MG and 
A-172 cell lines, respectively, as well as more enriched 
protein interaction networks. However, the use of either of 
the LFQ methods did not affect the main conclusions of the 
study. Therefore, here we show the results obtained using 
the SIN method.
Statistical analysis
Statistical analysis was performed using a Python 
module statsmodels, which implements many known 
statistical models (http://statsmodels.sourceforge.net/). The 
rationale for the statistical test choice is based on published 
recommendations [73]. Provided that our data originate 
from the same cell lines measured before and after the 
treatment, and that our goal is to identify protein changes 
occurring after the treatment, we have chosen a statistical 
test to compare two groups of dependent samples, namely, 
not treated against treated. According to [73], that could 
be the paired t-test for normally distributed (ND) data. 
For each identified protein, we evaluated statistically 
significant variations between ten measurements of the 
protein abundance in the control samples (5 LC-MS/MS 
technical replicates X 2 biological sample repetitions) and 
ten measurements of abundance for this protein in the 
IFN-treated samples (5 technical replicates X 2 biological 
repetitions). LFQ values for proteins unidentified in some 
sample replicates were either equaled to zero or imputed 
(see below). Corrections for multiple comparisons were 
taken into account. We considered Benjamini-Hochberg 
false discovery rate (FDR) for correcting p-values. Level 
of significance for corrected p-values was set to 0.05. To 
check normal distribution, the Shapiro-Wilk normality test 
was run for the data. Approximately 50% of the data has 
passed the normality test, while the remaining data has 
observed outliers, mainly due to missing measurements 
for some proteins. As recommended in [73], we run non-
parametric tests for the data with not normal distribution 
(NND). Wilcoxon and Friedman tests have demonstrated 
a loss of statistical power due to the small sample size (10 
measurements vs. ≥ 20 required), while Kruskal-Wallis 
test has shown a reasonable performance. Finally, we 
tested and compared three statistical workflows: (A) The 
paired t-test applied to both ND and NND data with the 
Benjamini-Hochberg FDR correction; (B) The paired t-test 
and the Kruskal-Wallis test followed by the Benjamini-
Hochberg FDR correction, applied to the ND and NND 
data, respectively; and (C) The paired t-test (ND, fdrBH)/
Kruskal-Wallis test (NND, fdrBH) applied to the data after 
imputation of missing protein identifications. One of 
the reasons for missing protein identifications is that the 
protein can be omitted by target-decoy filtering in some 
technical runs. To address this issue, we retrieved the 
unfiltered list of identified proteins for the proteins with 
missing values. If a protein was found in the unfiltered 
list, the missing value was imputed by the respective 
normalized spectral index. Otherwise, the protein was 
treated as absent or being under the detection limit and the 
missing value was equaled to zero. Such missing value 
strategy combined with a complementary evaluation of 
ND and NND data allowed revealing extra proteins and 
provided a better insight into the signaling pathways 
(Supplementary Information, Supplementary Table 2, 3). 
Note that the latter strategy can be considered as an 
analogue to lowering the threshold for filtering the results 
of statistical analysis. Comparison of statistical workflows 
and main results on differentially expressed proteins are 
provided in Supplementary Information (Supplementary 
Figure 1, Supplementary Tables 1–3). The strategy of a 
complementary use of the parametric and non-parametric 
statistical tests for an evaluation of ND and NND data is 
similar to the approach proposed in [74].
Gene ontology and IFN-regulated genes (IRGs) 
analysis
Genes encoding the proteins with statistically 
significant changes in expression were searched against 
the INTERFEROME v2.01 database [72], containing 
type I, II, and III IFN-regulated genes, compiled using 
publicly available microarray datasets (http://interferome.
its.monash.edu.au/interferome/home.jspx). Specified 
search parameters were as follows: type I IFNα, Homo 
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sapiens, nervous system, brain. Additionally, differentially 
expressed proteins were analyzed using STRING v.10.0 
database [57] to reveal physical and/or functional protein-
protein interactions (http://string-db.org/). For evaluation, 
protein names were submitted as they are given in the 
reviewed SwissProt db; default statistical background was 
the whole genome. Also, GOrilla tool [58] was used for 
identifying enriched processes allowing an analysis of 
a target list of genes against the user-defined statistical 
background (http://cbl-gorilla.cs.technion.ac.il/). The 
combined proteome of treated and untreated lines (either 
A-172 or DBTRG-05MG, respectively) was set as a 
background.
ACKNOWLEDGMENTS
Propagation of GBM cells, real-time qPCR, 
testing cell sensitivity to VSV western blot analyses and 
treatment with IFN was supported by the Russian Science 
Foundation (project #14-50-00060 to P.M.C.). Proteomic 
data processing, statistical and pathway analyses were 
performed using bioinformatic resources developed with 
the support from the Russian Science Foundation (project 
#14-14-00971 to M.V.G.). LC-MS/MS data collection and 
instrumental infrastructure was supported by the European 
Research Council (ERC) under the European Union’s 
Horizon 2020 Research and Innovation Programme 
(grant agreement No 646603 to F.K.), the Danish Council 
for Independent Research (0602-02691B to F.K.) and 
the VILLUM Center for Bioanalytical Sciences at the 
University of Southern Denmark. Sample preparation 
for LC-MS/MS analyses was supported by the Federal 
Agency of Scientific Organizations, Russia, to the Institute 
of Biomedical Chemistry (Project #1 “Post-genome 
biomarker discovery for socially important diseases and 
methods for detection thereof” to S.A.M.).  The cost of 
this publication was covered by SATOR Therapeutics 
LLC.
CONFLICTS OF INTEREST
None.
REFERENCES
 1. Delgado-Lopez PD, Corrales-Garcia EM. Survival 
in glioblastoma: a review on the impact of treatment 
modalities. Clin Transl Oncol. 2016; 18:1062–71. https://
doi.org/10.1007/s12094-016-1497-x.
 2. Omuro A, DeAngelis LM. Glioblastoma and other 
malignant gliomas: a clinical review. Jama. 2013; 
310:1842–50. https://doi.org/10.1001/jama.2013.280319.
 3. Demuth T, Berens ME. Molecular mechanisms of glioma 
cell migration and invasion. J Neurooncol. 2004; 70:217–
28. https://doi.org/10.1007/s11060-004-2751-6.
 4. Natsume A, Kato T, Kinjo S, Enomoto A, Toda H, Shimato 
S, Ohka F, Motomura K, Kondo Y, Miyata T, Takahashi 
M, Wakabayashi T. Girdin maintains the stemness of 
glioblastoma stem cells. Oncogene. 2012; 31:2715–24. 
https://doi.org/10.1038/onc.2011.466.
 5. De Bacco F, D’Ambrosio A, Casanova E, Orzan F, Neggia 
R, Albano R, Verginelli F, Cominelli M, Poliani PL, 
Luraghi P, Reato G, Pellegatta S, Finocchiaro G, et al. MET 
inhibition overcomes radiation resistance of glioblastoma 
stem-like cells. EMBO Mol Med. 2016; 8:550–68. https://
doi.org/10.15252/emmm.201505890.
 6. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie 
SG, Parada LF. A restricted cell population propagates 
glioblastoma growth after chemotherapy. Nature. 2012; 
488:522–6. https://doi.org/10.1038/nature11287.
 7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland 
AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells 
promote radioresistance by preferential activation of the 
DNA damage response. Nature. 2006; 444:756–60. 
 8. Brennan CW, Verhaak RG, McKenna A, Campos B, 
Noushmehr H, Salama SR, Zheng S, Chakravarty D, 
Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu 
CJ, et al. The somatic genomic landscape of glioblastoma. 
Cell. 2013; 155:462–77. https://doi.org/10.1016/j.
cell.2013.09.034.
 9. Wilson TA, Karajannis MA, Harter DH. Glioblastoma 
multiforme: State of the art and future therapeutics. Surg 
Neurol Int. 2014; 5:64. https://doi.org/10.4103/2152-
7806.132138.
10. Wainwright DA, Nigam P, Thaci B, Dey M, Lesniak MS. 
Recent developments on immunotherapy for brain cancer. 
Expert Opin Emerg Drugs. 2012; 17:181–202. https://doi.
org/10.1517/14728214.2012.679929.
11. Foreman PM, Friedman GK, Cassady KA, Markert JM. 
Oncolytic Virotherapy for the Treatment of Malignant 
Glioma. Neurotherapeutics. 2017; 14:333–44. https://doi.
org/10.1007/s13311-017-0516-0.
12. Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang 
WK, Moon A, Mun JH, Sommermann EM, Maruri Avidal 
L, Patt R, Pelusio A, Burke J, et al. Phase 1b Trial of 
Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and 
Immunotherapeutic Vaccinia Virus in Colorectal Cancer. 
Mol Ther. 2015; 23:1532–40. https://doi.org/10.1038/
mt.2015.109.
13. Ning J, Wakimoto H, Rabkin SD. Immunovirotherapy 
for glioblastoma. Cell Cycle. 2014; 13:175–6. https://doi.
org/10.4161/cc.27039.
14. Kaufmann JK, Chiocca EA. Glioma virus therapies 
between bench and bedside. Neuro Oncol. 2014. https://
doi.org/10.1093/neuonc/not310.
15. Cheema TA, Fecci PE, Ning J, Rabkin SD. 
Immunovirotherapy for the treatment of glioblastoma. 
Oncoimmunology. 2014; 3:e27218. https://doi.org/10.4161/
onci.27218.
Oncotarget1800www.impactjournals.com/oncotarget
16. Wollmann G, Ozduman K, van den Pol AN. Oncolytic 
virus therapy for glioblastoma multiforme: concepts and 
candidates. Cancer J. 2012; 18:69–81. 
17. Bell J, McFadden G. Viruses for Tumor Therapy. Cell 
Host Microbe. 2014; 15:260–5. https://doi.org/10.1016/j.
chom.2014.01.002.
18. Breitbach CJ, Lichty BD, Bell JC. Oncolytic Viruses: 
Therapeutics With an Identity Crisis. EBioMedicine. 2016; 
9:31–6. https://doi.org/10.1016/j.ebiom.2016.06.046.
19. Donnelly O, Harrington K, Melcher A, Pandha H. Live 
viruses to treat cancer. J R Soc Med. 2013; 106:310–4. 
https://doi.org/10.1177/0141076813494196.
20. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat 
Biotechnol. 2012; 30:658–70. 
21. Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic 
Viruses in Cancer Treatment: A Review. JAMA Oncol. 
2016. https://doi.org/10.1001/jamaoncol.2016.2064.
22. Keller BA, Bell JC. Oncolytic viruses-immunotherapeutics 
on the rise. J Mol Med (Berl). 2016; 94:979–91. https://doi.
org/10.1007/s00109-016-1453-9.
23. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A 
new era of cancer treatment at dawn. Cancer Sci. 2016; 
107:1373–9. https://doi.org/10.1111/cas.13027.
24. Zamarin D, Pesonen S. Replication-Competent Viruses 
as Cancer Immunotherapeutics: Emerging Clinical Data. 
Hum Gene Ther. 2015; 26:538–49. https://doi.org/10.1089/
hum.2015.055.
25. Workenhe ST, Verschoor ML, Mossman KL. The role of 
oncolytic virus immunotherapies to subvert cancer immune 
evasion. Future Oncol. 2015; 11:675–89. https://doi.
org/10.2217/fon.14.254.
26. Warner SG, Haddad D, Au J, Carson JS, O’Leary MP, Lewis C, 
Monette S, Fong Y. Oncolytic herpes simplex virus kills stem-
like tumor-initiating colon cancer cells. Mol Ther Oncolytics. 
2016; 3:16013. https://doi.org/10.1038/mto.2016.13.
27. Tong Y, Qian W. Targeting cancer stem cells with 
oncolytic virus. Stem Cell Investig. 2014; 1:20. https://doi.
org/10.3978/j.issn.2306-9759.2014.11.01.
28. Zeng W, Hu P, Wu J, Wang J, Li J, Lei L, Liu R. The 
oncolytic herpes simplex virus vector G47 effectively 
targets breast cancer stem cells. Oncol Rep. 2013; 29:1108–
14. https://doi.org/10.3892/or.2012.2211.
29. Wang H, Chen NG, Minev BR, Szalay AA. Oncolytic 
vaccinia virus GLV-1h68 strain shows enhanced replication 
in human breast cancer stem-like cells in comparison to 
breast cancer cells. J Transl Med. 2012; 10:167. https://doi.
org/10.1186/1479-5876-10-167.
30. Allen C, Opyrchal M, Aderca I, Schroeder MA, Sarkaria 
JN, Domingo E, Federspiel MJ, Galanis E. Oncolytic 
measles virus strains have significant antitumor activity 
against glioma stem cells. Gene Ther. 2012; 23:62. 
31. Alonso MM, Jiang H, Gomez-Manzano C, Fueyo 
J. Targeting brain tumor stem cells with oncolytic 
adenoviruses. Methods Mol Biol. 2012; 797:111–25. 
32. Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker 
I, Ball CR, Johnston IC, Lauer UM, Herold-Mende 
C, Muhlebach MD, Glimm H, Buchholz CJ. Specific 
elimination of CD133+ tumor cells with targeted oncolytic 
measles virus. Cancer Res. 2013; 73:865–74. https://doi.
org/10.1158/0008-5472.can-12-2221.
33. Dey M, Ulasov IV, Tyler MA, Sonabend AM, Lesniak MS. 
Cancer stem cells: the final frontier for glioma virotherapy. 
Stem Cell Rev. 2011; 7:119–29. 
34. McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, 
McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA. 
In vitro screen of a small molecule inhibitor drug library 
identifies multiple compounds that synergize with oncolytic 
myxoma virus against human brain tumor-initiating cells. 
Neuro Oncol. 2015. https://doi.org/10.1093/neuonc/nou359.
35. van den Hengel SK, Balvers RK, Dautzenberg IJ, van den 
Wollenberg DJ, Kloezeman JJ, Lamfers ML, Sillivis-Smit 
PA, Hoeben RC. Heterogeneous reovirus susceptibility in 
human glioblastoma stem-like cell cultures. Cancer Gene 
Ther. 2013; 20:507–13. https://doi.org/10.1038/cgt.2013.47.
36. Csatary LK, Bakacs T. Use of Newcastle disease virus 
vaccine (MTH-68/H) in a patient with high-grade 
glioblastoma. JAMA. 1999; 281:588–9. 
37. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, 
Bodey B, Csatary CM. MTH-68/H oncolytic viral treatment 
in human high-grade gliomas. J Neurooncol. 2004; 67:83–
93. 
38. Liu TC, Galanis E, Kirn D. Clinical trial results with 
oncolytic virotherapy: a century of promise, a decade of 
progress. Nat Clin Pract Oncol. 2007; 4:101–17. 
39. Whisenhunt TR Jr, Rajneesh KF, Hackney JR, Markert 
JM. Extended disease-free interval of 6 years in a recurrent 
glioblastoma multiforme patient treated with G207 
oncolytic viral therapy. Oncolytic Virother. 2015; 4:33–8. 
https://doi.org/10.2147/ov.s62461.
40. Pikor LA, Bell JC, Diallo JS. Oncolytic viruses: exploiting 
cancer’s deal with the Devil. Trends in Cancer. 2015; 
1:266–77. 
41. Matveeva OV, Guo ZS, Shabalina SV, Chumakov PM. 
Oncolysis by paramyxoviruses: multiple mechanisms 
contribute to therapeutic efficacy Molecular Therapy - 
oncolytics. 2015; 2:15011. 
42. Sangfelt, Strander H. Apoptosis and cell growth inhibition 
as antitumor effector functions of interferons. Med Oncol. 
2001; 18:3–14. 
43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next 
generation. Cell. 2011; 144:646–74. 
44. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, 
Sonenberg N, Bell JC. Exploiting tumor-specific defects in 
the interferon pathway with a previously unknown oncolytic 
virus. Nat Med. 2000; 6:821–5. 
45. Katsoulidis E, Kaur S, Platanias LC. Deregulation of 
interferon signaling in malignant cells. Pharmaceuticals. 
2010; 3:406–18. 
Oncotarget1801www.impactjournals.com/oncotarget
46. Li Q, Tainsky MA. Epigenetic silencing of IRF7 and/or 
IRF5 in lung cancer cells leads to increased sensitivity to 
oncolytic viruses. PLoS One. 2011; 6:e28683. https://doi.
org/10.1371/journal.pone.0028683.
47. Heiber JF, Barber GN. Evaluation of innate immune 
signaling pathways in transformed cells. Methods Mol Biol. 
2012; 797:217–38. 
48. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer 
G. Type I interferons in anticancer immunity. Nat Rev 
Immunol. 2015; 15:405–14. https://doi.org/10.1038/
nri3845.
49. Li S, Zhu M, Pan R, Fang T, Cao YY, Chen S, Zhao X, 
Lei CQ, Guo L, Chen Y, Li CM, Jokitalo E, Yin Y, et al. 
The tumor suppressor PTEN has a critical role in antiviral 
innate immunity. Nat Immunol. 2016; 17:241–9. https://doi.
org/10.1038/ni.3311.
50. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. 
Immunity. 2012; 36:503–14. https://doi.org/10.1016/j.
immuni.2012.03.013.
51. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT 
signaling pathway. J Cell Sci. 2004; 117:1281–3. https://
doi.org/10.1242/jcs.00963.
52. Kotredes KP, Gamero AM. Interferons as inducers of 
apoptosis in malignant cells. J Interferon Cytokine Res. 
2013; 33:162–70. https://doi.org/10.1089/jir.2012.0110.
53. Parker BS, Rautela J, Hertzog PJ. Antitumour actions 
of interferons: implications for cancer therapy. Nat 
Rev Cancer. 2016; 16:131–44. https://doi.org/10.1038/
nrc.2016.14.
54. Zaidi MR, Merlino G. The two faces of interferon-gamma 
in cancer. Clin Cancer Res. 2011; 17:6118–24. https://doi.
org/10.1158/1078-0432.ccr-11-0482.
55. Schoggins JW, Rice CM. Interferon-stimulated genes 
andtheir antiviral effector functions. Curr Opin Virol. 
2011;1:519–25. https://doi.org/10.1016/j.coviro.2011.10.008.
56. Rusinova I, Forster S, Yu S, Kannan A, Masse M, 
Cumming H, Chapman R, Hertzog PJ. Interferome v2.0: 
an updateddatabase of annotated interferon-regulated 
genes. Nucleic Acids Res. 2013; 41:D1040–6. https://doi.
org/10.1093/nar/gks1215. 
57. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller 
D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou 
KP, Kuhn M, Bork P, Jensen LJ, et al. STRING v10:protein-
protein interaction networks, integrated over thetree of 
life. Nucleic Acids Res. 2015; 43:D447–52. https://doi.
org/10.1093/nar/gku1003.
58. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla:a 
tool for discovery and visualization of enriched GO termsin 
ranked gene lists. BMC Bioinformatics. 2009; 10:48.https://
doi.org/10.1186/1471-2105-10-48.
59. Beatty GL, Gladney WL. Immune escape mechanisms 
asa guide for cancer immunotherapy. Clin Cancer Res. 
2015;21:687–92. https://doi.org/10.1158/1078-0432.ccr-
14-1860.
60. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The 
roleof JAK/STAT signalling in the pathogenesis, prognosis 
andtreatment of solid tumours. Br J Cancer. 2015; 113:365–
71.https://doi.org/10.1038/bjc.2015.233.
61. Basu M, Maitra RK, Xiang Y, Meng X, Banerjee AK, 
Bose S. Inhibition of vesicular stomatitis virus infectionin 
epithelial cells by alpha interferon-induced solublesecreted 
proteins. J Gen Virol. 2006; 87:2653–62. https://doi.
org/10.1099/vir.0.82039-0.
62. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun 
L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU. 
TRIM25RING-finger E3 ubiquitin ligase is essential for 
RIG-I-mediated antiviral activity. Nature. 2007; 446:916–
20.https://doi.org/10.1038/nature05732.
63. Mazza M, Pelicci PG. Is PML a Tumor Suppressor?Front 
Oncol. 2013; 3:174. https://doi.org/10.3389/
fonc.2013.00174.
64. Groner B, von Manstein V. Jak Stat signaling and 
cancer:Opportunities, benefitsand side effects of 
targetedinhibition. Mol Cell Endocrinol. 2017; 451:1–14. 
https://doi.org/10.1016/j.mce.2017.05.033.
65. Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese 
P, Sharma P, Merghoub T, Wolchok JD, Allison JP. 
Intratumoral modulation of the inducible co-stimulator 
ICOS by recombinant oncolytic virus promotes systemic 
anti-tumour immunity. Nat Commun. 2017; 8:14340. 
https://doi.org/10.1038/ncomms14340.
66. Laemmli UK. Cleavage of structural proteins during the 
assembly of the head of bacteriophage T4. Nature. 1970; 
227:680–5.
67. Ivanov M, Levitsky L, Tarasova I, Gorshkov M. 
Pepxmltk—a format converter for peptide identification 
results obtained from tandem mass spectrometry data using 
X! Tandem search engine. J Anal Chem. 2015; 70:1598–9.
68. Elias JE, Gygi SP. Target-decoy search strategy for 
increased confidencein large-scale protein identifications by 
mass spectrometry. Nat Methods. 2007; 4:207–14. https://
doi.org/10.1038/nmeth1019.
69. Ivanov MV, Levitsky LI, Lobas AA, Panic T, Laskay UA, 
Mitulovic G, Schmid R, Pridatchenko ML, Tsybin YO, 
Gorshkov MV. Empirical multidimensional space for 
scoring peptide spectrum matches in shotgun proteomics. J 
Proteome Res. 2014; 13:1911–20. https://doi.org/10.1021/
pr401026y.
70. Griffin NM, Yu J, Long F, Oh P, Shore S, Li Y, Koziol 
JA, Schnitzer JE. Label-free, normalized quantification of 
complex mass spectrometry data for proteomic analysis. 
Nat Biotechnol. 2010; 28:83–9. doi: 10.1038/nbt.1592.
71. Zybailov BL, Florens L, Washburn MP. Quantitative 
shotgun proteomics using a protease with broad specificity 
and normalized spectral abundance factors. Mol Biosyst. 
2007; 3:354–60. https://doi.org/10.1039/b701483j.
72. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber 
J, Mann M. Exponentially modified protein abundance 
Oncotarget1802www.impactjournals.com/oncotarget
index (emPAI) for estimation of absolute protein amount 
in proteomics by the number of sequenced peptides per 
protein. Mol Cell Proteomics. 2005; 4:1265–72. https://doi. 
org/10.1074/mcp.M500061-MCP200.
73. Motulsky HJ. Intuitive Biostatistics, Edition: 3rd, Appendix 
F, Choosing a Statistical Test. : Oxford University Press). 
2014.
74. Schwammle V, Leon IR, Jensen ON. Assessment and 
improvement of statistical tools for comparative proteomics 
analysis of sparse data sets with few experimental 
replicates. J Proteome Res. 2013; 12:3874–83. https://doi.
org/10.1021/pr400045u.
